Towards Healthcare

Microfluidics Manufacturers and Recent Development

Date : 11 November 2025

Spotlight on the Companies Driving Growth in the Microfluidics Market

Microfluidics Market Companies

Know About the Industry

A system that manipulates a limited number of fluids through tiny channels that range in size from ten to hundreds of micrometers is known as microfluidics. The study of fluid behavior through microchannels and the technology for creating microminiaturized devices with chambers and tunnels that allow fluids to flow or be contained are combined to form the microfluidics market. Molecular biology, microelectronics, and analysis are all interdisciplinary fields that are part of the microfluidics business. It may be usefully incorporated into the design of low-volume fluid processing systems to accomplish high-throughput screening, multiplexing and automation. The increasing use of microfluidics technology and devices in point-of-care diagnostics, the development of diagnostic devices through technology, and the global rise in the prevalence of chronic illnesses are the main drivers of the microfluidics market.

Market Growth

The global microfluidics market size is anticipated to grow from USD 40.25 billion in 2025 to USD 116.17 billion by 2034, with a compound annual growth rate (CAGR) of 12.50% during the forecast period from 2025 to 2034.

  • In April 2025, Truenat HPV-HR Plus, which is a high-risk genotype detection system, was launched by Molbio Diagnostics as a point-of-care molecular diagnostic. The fast and decentralized detection of eight high-risk genotypes of human papillomavirus (HPV) can be carried out using this chip-based RT-PCR test, which is a leading cause of cervical cancer cases globally.
  • In April 2025, a strategic collaboration was formed between CN Bio, which provides Organ-on-a-chip systems and solutions for improving drug discovery and development, with Pharmaron, which is a life sciences R&D service provider. In this collaboration, CN Bio’s PhysioMimix technology for current applications will be validated by Pharmaron and will incorporate OOC technologies into its R&D platform.  Furthermore, they will identify new applications to tackle unmet requirements in drug discovery and development.

Key Players and Components in the Microfluidics Market Ecosystem

  • The microfluidics market ecosystem is shaped by several core components and leading companies that drive innovation and growth. At its heart, microfluidics involves precise control of fluid flows in micro-scale channels, essential for applications in diagnostics, drug delivery, and biological research.
  • Key components of this ecosystem include microfluidic devices, which integrate microchannels, sensors, and valves to manipulate small volumes of fluids. These devices are critical in lab-on-a-chip systems, enabling rapid and efficient analysis.
  • Leading companies in the microfluidics market contribute significantly by developing and refining these technologies. For instance, companies like Illumina and Fluidigm focus on advanced microfluidic devices for genomics and proteomics. PerkinElmer and Agilent Technologies provide sophisticated microfluidic systems for analytical and clinical applications. Dolomite Microfluidics and Syrris are known for their innovative microfluidic components and solutions, enhancing lab automation and chemical synthesis. LabSmith and Micronit Microtechnologies offer customizable microfluidic platforms for a wide range of research and industrial needs.
  • Together, these components and companies create a dynamic and evolving microfluidics ecosystem, pushing the boundaries of scientific discovery and practical applications.

Recent Developments in the Microfluidics Market

1. Takara Bio Inc.

  • Headquarters: Shiga, Japan, Asia Pacific

  • Date: May 2024

  • Overview: Takara Bio U.S., Inc., a wholly-owned subsidiary of Takara Bio Inc., introduced the Lenti-X Transduction Sponge, the first dissolvable microfluidic transduction enhancer available in the market.

  • Key Features:

    • Designed specifically for in vitro lentivirus-mediated gene delivery methods.

    • Achieves high transduction efficiency across any cell type.

    • Offers a simple, walkaway workflow, making it user-friendly and efficient.

  • Impact: Opens new research possibilities in gene and cell therapy, setting a benchmark for innovation in microfluidic-based genetic engineering tools.

2. RedShiftBio

  • Headquarters: Massachusetts, U.S., North America

  • Date: May 2024

  • Overview: During the Protein & Antibody Engineering Summit (PEGS) in Boston, RedShiftBio, a leader in biophysical characterization and bioprocess analytical technologies, announced the launch of its Aurora TX instrument.

  • Key Features:

    • Employs microfluidic modulation spectroscopy (MMS) for highly accurate biomolecular analysis.

    • Provides ultra-sensitive and ultra-precise measurements of biomolecule stability and structure.

    • Now equipped with an added thermal ramping capability, enhancing performance and flexibility.

  • Impact: Sets a new industry standard in biomolecular analysis, enabling researchers to perform advanced protein characterization with greater precision and efficiency.

Recent Developments in the Microfluidics Market

  • In May 2024, scientists at the National Institute of Standards and Technology (NIST) created bioelectronic instruments that can analyze cell activities in real-time. Researchers are including these elements in their adaptation of the heart-on-a-chip (HoC) system. With a heavy reliance on animal testing, traditional cardiovascular medication research has several shortcomings that this approach aims to solve. The Human Cardiac Model (HoC) has the potential to expedite drug development and save costs by substituting animal research with a more realistic model of the human body, which may capture important characteristics of the human cardiovascular system in a lab setting.
  • In April 2024, Boston Micro Fabrication (BMF) is pleased to announce the establishment of BMF Biotechnology Inc. to further facilitate the application of extremely accurate microfluidic solutions in advanced drug development, pharmaceutical, and cosmetic research. BMF Biotechnology Inc., a California company with its headquarters in San Diego, is committed to creating and marketing cutting-edge BioChips, organs-on-a-chip platforms, by growing large-scale tissues in vitro and accelerating the development of novel drugs and cosmetics.
  • In March 2023, in droplet microfluidic applications, a novel technique utilizing on-chip fiber optics allows for multiplexed fluorescence and scatter detection with previously unheard-of single-cell precision, according to a paper published in the journal Microsystems & Nanoengineering.
  • In May 2023, researchers at the University of Birmingham established a route towards 3D-bioprinted microfluidic tissues, organs, and arteries. By employing 3D bioprinting, research from the University of Birmingham may be able to shorten the lengthy waiting lists for organ transplants. The group claims that its research will hasten the implementation of microfluidic-based tissue in collaboration with collaborators at the University of Huddersfield and the Polytechnic University of Milan.

Partner with our experts to explore the Microfluidic Market at sales@towardshealthcare.com